Skip to main content
Dechra Pharmaceuticals PLC logo

Dechra Pharmaceuticals PLC — Investor Relations & Filings

Ticker · DPH ISIN · US2434351043 LEI · 213800J4UVB5OWG8VX82 IL Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2023-11-22 Major Shareholding Noti…
Country GB United Kingdom
Listing IL DPH

About Dechra Pharmaceuticals PLC

https://www.dechra.com/

Dechra Pharmaceuticals PLC is a global specialist business focused on veterinary pharmaceuticals and related products. The company's expertise encompasses the development, manufacture, marketing, and sale of high-quality veterinary medicines. Its product portfolio includes both novel and differentiated generic pharmaceuticals, with a significant focus on products for companion animals. Dechra provides solutions and support to veterinary professionals worldwide to improve animal health and welfare.

Recent filings

Filing Released Lang Actions
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'FORM 8.3 - Dechra Pharmaceuticals plc' and references 'Rule 8.3 of the Takeover Code (the “Code”)'. This form is a Public Opening Position Disclosure or Dealing Disclosure made by a person holding 1% or more interests in relevant securities during a takeover situation. This type of filing relates specifically to insider/significant shareholder activity during a takeover bid, which falls under the scope of M&A activity or specific regulatory disclosures related to takeovers. Since there is a specific category for M&A Activity (TAR), and this document is a direct disclosure related to a potential takeover (indicated by the reference to the Takeover Code and the disclosure of interests in securities of the offeree), TAR is the most appropriate classification. It is not a general Director's Dealing (DIRS) as it is tied to a specific takeover event under the Takeover Code rules.
2023-11-22 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is clearly identified as an 'RNS Number' filing from 'Dechra Pharmaceuticals PLC' dated '22 November 2023'. The core content is structured as 'TR-1: Standard form for notification of major holdings', detailing changes in voting rights held by JPMorgan Chase & Co. This specific form (TR-1) is used in the UK/EU regulatory framework to report changes in major shareholdings, which falls under notifications of significant ownership changes. This aligns perfectly with the definition for Major Shareholding Notification (MRQ). Although it is distributed via RNS, the content itself is a specific regulatory disclosure about share ownership thresholds being crossed.
2023-11-22 English
Rule 2.9 Announcement
M&A Activity Classification · 99% confidence The document is identified by the 'RNS Number' header and explicitly states it is a 'Rule 2.9 Announcement' under the 'City Code on Takeovers and Mergers (the "Code")'. Rule 2.9 announcements require the company to confirm the total number of shares in issue when a takeover offer is in effect. This type of mandatory disclosure related to corporate actions, specifically takeovers and share capital confirmation, is a regulatory filing. Since it is a specific regulatory announcement concerning share capital during a potential takeover scenario, and it is distributed via RNS (the London Stock Exchange news service), it fits best under the general 'Regulatory Filings' category (RNS) as it is not a specific report like 10-K, IR, or ER, nor is it a Director's Dealing (DIRS) or a general Capital Change (CAP). Given the context of mandatory disclosure under the Takeover Code, RNS is the most appropriate general regulatory classification.
2023-11-21 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled "FORM 8.3 - Dechra Pharmaceuticals plc" and references "Rule 8.3 of the Takeover Code (the “Code”)". This form is a Public Opening Position Disclosure/Dealing Disclosure made by a person with interests representing 1% or more in relevant securities during a takeover situation. This type of filing relates to insider transactions or significant ownership changes during a takeover bid, which falls under the scope of M&A activity or significant shareholding notifications, but the specific nature of reporting director/insider dealings during a takeover context aligns most closely with the intent behind tracking insider transactions, although it is highly specific to M&A rules. Given the options, this document details the interests and dealings of a major shareholder (Millennium International Management LP) concerning securities of an offeree (Dechra Pharmaceuticals plc) during what is implied to be a takeover process (due to the reference to the Takeover Code and Form 8.3). While it involves share dealings, it is not a standard Director's Dealing (DIRS) report (Form 4/3/5 equivalent) but a specific M&A-related disclosure. Since the core context is a takeover/merger situation, the most appropriate category is M&A Activity (TAR), as Form 8.3 is mandatory during such events. If TAR was not available, DIRS might be considered, but TAR captures the context better.
2023-11-21 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains detailed tables regarding the acquisition or disposal of voting rights by a shareholder (Bank of America Corporation) in the issuer (Dechra Pharmaceuticals PLC). This structure and content perfectly match the definition of a Major Shareholding Notification, which is categorized under the code MRQ in the provided schema. The presence of RNS numbering and the LSE disclaimer confirms it is a regulatory filing, but MRQ is the specific type for major holding changes.
2023-11-21 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is titled 'TR-1: Standard form for notification of major holdings' and is issued via 'RNS Number : 1170U' on '21 November 2023'. This form is used to report changes in major shareholdings (crossing thresholds) as required by regulatory bodies (implied by the RNS/FCA context). The content details the resulting situation of voting rights and financial instruments held by JPMorgan Chase & Co. This directly corresponds to the definition of a Major Shareholding Notification.
2023-11-21 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.